Company insider · SEC Form 4

Martine Rothblatt

United Therapeutics Corporation (UTHR)

SEC Form 4 data · Jul 01, 2024Jun 30, 2026

Martine Rothblatt's stock sales and purchases

Every open-market purchase and sale Martine Rothblatt reported on Form 4 over two years, as SEC lists the filer: “Rothblatt Martine A”. Grants, option exercises and gifts are not trades and are left out.

Bought
Sold
$616.1M
Trades
1,424
Sales on a 10b5-1 plan
100%

UTHRUnited Therapeutics CorporationChairperson & CEO

1,424 sales worth $616.1M (1419 on a 10b5-1 plan). Largest sale: $2.5M on May 22, 2026.

QuarterBoughtSold
Q2 2026$326.7M655 sales · all on a plan
Q1 2026$110.6M287 sales · all on a plan
Q4 2025$104.5M174 sales · all on a plan
Q3 2025$28M34 sales · 29 on a plan
Q3 2024$46.3M274 sales · all on a plan

Most recent trades30 of 1,424

  • Martine Rothblatt10b5-1

    Chairperson & CEO · Director

    $1.2M

    Jun 29, 2026

    2,165 sh · $545.30

  • Martine Rothblatt10b5-1

    Chairperson & CEO · Director

    $933.2K

    Jun 29, 2026

    1,702 sh · $548.29

  • Martine Rothblatt10b5-1

    Chairperson & CEO · Director

    $931.4K

    Jun 29, 2026

    1,705 sh · $546.28

  • Martine Rothblatt10b5-1

    Chairperson & CEO · Director

    $867.8K

    Jun 29, 2026

    1,594 sh · $544.40

  • Martine Rothblatt10b5-1

    Chairperson & CEO · Director

    $415.3K

    Jun 29, 2026

    759 sh · $547.12

  • Martine Rothblatt10b5-1

    Chairperson & CEO · Director

    $317.9K

    Jun 29, 2026

    585 sh · $543.37

  • Martine Rothblatt10b5-1

    Chairperson & CEO · Director

    $236.1K

    Jun 29, 2026

    430 sh · $548.96

  • Martine Rothblatt10b5-1

    Chairperson & CEO · Director

    $194.8K

    Jun 29, 2026

    360 sh · $541.24

  • Martine Rothblatt10b5-1

    Chairperson & CEO · Director

    $64.8K

    Jun 29, 2026

    120 sh · $539.98

  • Martine Rothblatt10b5-1

    Chairperson & CEO · Director

    $43.3K

    Jun 29, 2026

    80 sh · $541.86

  • Martine Rothblatt10b5-1

    Chairperson & CEO · Director

    $1.2M

    Jun 26, 2026

    2,128 sh · $541.24

  • Martine Rothblatt10b5-1

    Chairperson & CEO · Director

    $549.8K

    Jun 26, 2026

    1,012 sh · $543.32

  • Martine Rothblatt10b5-1

    Chairperson & CEO · Director

    $549.6K

    Jun 26, 2026

    1,018 sh · $539.89

  • Martine Rothblatt10b5-1

    Chairperson & CEO · Director

    $532.9K

    Jun 26, 2026

    983 sh · $542.14

  • Martine Rothblatt10b5-1

    Chairperson & CEO · Director

    $478.6K

    Jun 26, 2026

    872 sh · $548.90

  • Martine Rothblatt10b5-1

    Chairperson & CEO · Director

    $344.5K

    Jun 26, 2026

    640 sh · $538.34

  • Martine Rothblatt10b5-1

    Chairperson & CEO · Director

    $305.5K

    Jun 26, 2026

    560 sh · $545.52

  • Martine Rothblatt10b5-1

    Chairperson & CEO · Director

    $285.8K

    Jun 26, 2026

    520 sh · $549.69

  • Martine Rothblatt10b5-1

    Chairperson & CEO · Director

    $247.8K

    Jun 26, 2026

    452 sh · $548.13

  • Martine Rothblatt10b5-1

    Chairperson & CEO · Director

    $238.9K

    Jun 26, 2026

    439 sh · $544.18

  • Martine Rothblatt10b5-1

    Chairperson & CEO · Director

    $220.3K

    Jun 26, 2026

    400 sh · $550.79

  • Martine Rothblatt10b5-1

    Chairperson & CEO · Director

    $154.7K

    Jun 26, 2026

    280 sh · $552.36

  • Martine Rothblatt10b5-1

    Chairperson & CEO · Director

    $85.3K

    Jun 26, 2026

    156 sh · $547.00

  • Martine Rothblatt10b5-1

    Chairperson & CEO · Director

    $22.1K

    Jun 26, 2026

    40 sh · $553.49

  • Martine Rothblatt10b5-1

    Chairperson & CEO · Director

    $1M

    Jun 25, 2026

    1,814 sh · $551.61

  • Martine Rothblatt10b5-1

    Chairperson & CEO · Director

    $982.7K

    Jun 25, 2026

    1,778 sh · $552.68

  • Martine Rothblatt10b5-1

    Chairperson & CEO · Director

    $890.7K

    Jun 25, 2026

    1,617 sh · $550.86

  • Martine Rothblatt10b5-1

    Chairperson & CEO · Director

    $443.2K

    Jun 25, 2026

    800 sh · $553.97

  • Martine Rothblatt10b5-1

    Chairperson & CEO · Director

    $418.8K

    Jun 25, 2026

    762 sh · $549.55

  • Martine Rothblatt10b5-1

    Chairperson & CEO · Director

    $371.8K

    Jun 25, 2026

    684 sh · $543.54

From SEC's quarterly Form 3, 4 and 5 data sets through Jun 30, 2026; newer filings appear on each company's page and the live dashboard. A 10b5-1 plan fixes a sale's dates or amounts in advance. Monitoring, not advice.

Track Martine Rothblatt live — and everyone else

The dashboard reads every new filing within minutes: every Form 4 the moment it clears EDGAR, this person's included — plus live insider buying across the whole market, the most-bought board, and performance versus the S&P. Free to start.

Questions

How much UTHR stock has Martine Rothblatt sold?
Between Jul 01, 2024 and Jun 30, 2026, Martine Rothblatt sold $616.1M of United Therapeutics Corporation (UTHR) stock in 1,424 open-market sales, 1419 of them under a pre-arranged Rule 10b5-1 trading plan. The largest single sale was $2.5M on May 22, 2026.
Has Martine Rothblatt bought UTHR stock?
No open-market purchase of UTHR by Martine Rothblatt appears in SEC's Form 4 data for trades between Jul 01, 2024 and Jun 30, 2026. Share grants and option exercises are not counted as purchases.
Are Martine Rothblatt's stock sales planned in advance?
100% of the sales on record (1419 of 1424) were marked on the Form 4 as made under a Rule 10b5-1 plan, which fixes dates or amounts months ahead so the sale is not a reaction to that day's news. A planned sale says nothing about where the stock is going.
Where does this data come from?
From SEC's quarterly Form 3, 4 and 5 data sets. Company insiders like Martine Rothblatt — SEC lists the filer as "Rothblatt Martine A", role Chairperson & CEO — must report a trade in their company's stock within two business days. Only open-market purchases (code P) and sales (code S) are counted; grants, option exercises and gifts are not.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.